Medtech outlook 2013: Major environmental factors for the year ahead

rising and falling illustration

Wall Street analysts released their predictions for the major medical device industry trends of 2013, and the outlook isn’t much to celebrate.

In a report released late last year Leerink Swann analysts outlined a handful of predictions for 2013, generally projecting dampened sales growth and enduring, if not increasing, pricing and reimbursement pressures as frugality continues to drive healthcare.

"Today medtech companies face maturing end-markets, ongoing macroeconomic challenges, and a changing healthcare environment – all of which are likely to pressure growth acceleration prospects broadly speaking," analysts Danielle Antalffy and Richard Newitter wrote.

Challenges in the U.S. economic climate may spur an increase in medtech M&A activity, they added, and investors will look for companies with "exposure to new product cycles and/or faster-growing end-user markets," they added.

This year will also likely see more restructuring efforts and device makers cope with the medical device tax, and perhaps a stronger push into emerging markets in order to make up for the sluggish environment in developed markets.

The Swann analysts broke down their 2013 predictions into 9 parts:

  1. "Top-line growth acceleration in large-cap medtech likely muted" – That means about 3% sales growth for large-cap companies, with the exception of companies like Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NSDQ:ISRG). Those companies are operating in the transcatheter aortic valve and robot-assisted surgery segments, which the Swann analysts pegged as ones with faster-growing end-user markets.
  2. "More restructuring and op-ex cuts likely in an effort to offset the medtech tax" – Despite the industry’s best efforts device makers will start making their 1st device tax payments as early as this month, and they’re likely to have a hard time passing on that cost to customers given hospitals’ focus on driving down healthcare costs. Large-cap companies may turn to operational cuts, such as layoffs, in order to offset the new cost.
  3. “small-cap medtech path to profitability likely lengthened” – Smaller companies will generally have a tougher time absorbing the new medical device tax, meaning a longer road to profitability and possibly higher interest in selling to a larger company.
  4. “Industry price/volume/reimbursement pressures unlikely to dissipate and could even intensify” – Major medtech hurdles aren’t going anywhere in 2013, including economic turmoil in Europe, reimbursement pressure, high unemployment and related lack of access to healthcare and more physicians joining hospital groups in order to gain bargaining leverage. Other environmental factors may even get worse, such as the new Medicare cuts included in the fiscal cliff deal, a new Medicare bundled payment imitative that may favor older and cheaper devices, growing price and volume pressures as Accountable Care Organizations look for ways to trim costs from healthcare and a possible increase in scrutiny on procedures deemed controversial or unnecessary.
  5. “Further expansion into faster-growth emerging markets necessary to
    counter slowing growth trends in developed markets”
    – A significant portion of large medtech companies derive between 40%-60% of their revenue from markets outside the U.S., including from the so-called "BRIC" countries of Brazil, Russia, India and China, and those percentages are likely to grow in 2013. This year will likely see more overseas M&A and other measures designed to gain a foothold in emerging markets, including devices tailored to meet local technology and pricing needs.
  6. “Cardiology pricing and procedures likely still under pressure” – The cardiology slump, a major feature of the U.S. healthcare market for the past several years, will keep right on slumping. 2013 will see more declines in the large cardiology markets in the U.S., such as cardiac rhythm management devices and drug-eluting stents. Overseas cardiology markets may make a turnaround from last year’s slide to sees some modest growth this year.
  7. “In orthopedics, at best we expect stable price/volume trends” – The orthopedics market looks to be stagnant for this year as downward pricing pressures look to negate modest volume growth. The orthopedics extremities segment may see above-average growth, but pressure on spinal devices will keep that segment from making any "significant" moves in the next year. Some growth opportunities do exist, such as for MIS spine procedures, and smaller spine companies are poised to continue taking share from the big dogs.
  8. “Higher payout ratios likely on tap” – Device makers this year will likely focus on handing large sums back to shareholders as investors seem to be leaning toward companies with buyback and dividend plans rather than those that put their money back into their business. M&A activity is poised to be the top cash draw for large-cap device makers, but more companies may shift to higher payout strategies.
  9. “‘High growth’ medtech market opportunities are scarce … but ones that
    remain should continue to draw increasing levels of investor attention”
    – Top areas of interest in 2013 include transcatheter valves, left ventricular assist devices, cervical discs, renal denervation and robotics.

RSS From Medical Design & Outsourcing

  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]

Leave a Reply